key: cord-0712077-4dfbd7xo
authors: Weber, M.; Risch, M.; Thiel, S.; Grossmann, K.; Nigg, S.; Wohlwend, N.; Lung, T.; Hillmann, D.; Ritzler, M.; Ferrara, F.; Bigler, S.; Egli, K.; Bodmer, T.; Imperiali, M.; Salimi, Y.; Fleisch, F.; Cusini, A.; Heer, S.; Renz, H.; Paprotny, M.; Kohler, P.; Vernazza, P.; Risch, L.; Kahlert, C. R.
title: Characteristics of three different chemiluminescence assays for testing for SARS-CoV-2 antibodies
date: 2020-11-06
journal: nan
DOI: 10.1101/2020.11.05.20225003
sha: dba961faae5648aeab032d4dfa9f07946d9277a4
doc_id: 712077
cord_uid: 4dfbd7xo

Several tests based on chemiluminescence immunoassay techniques have become available to test for SARS CoV 2 antibodies. There is currently insufficient data on serology assay performance beyond 35 days after symptoms onset. We aimed to evaluate SARS CoV 2 antibody tests on three widely used platforms. A chemiluminescent microparticle immunoassay (CMIA; Abbott Diagnostics, USA), a luminescence immunoassay (LIA; Diasorin, Italy), and an electrochemiluminescence immunoassay (ECLIA; Roche Diagnostics, Switzerland) were investigated. In a multigroup study, sensitivity was assessed in a group of participants with confirmed SARS CoV 2 (n=145), whereas specificity was determined in two groups of participants without evidence of COVID 19 (i.e. healthy blood donors, n=191, and healthcare workers, n=1002). Receiver operating characteristic (ROC) curves, multilevel likelihood ratios (LR), and positive (PPV) and negative (NPV) predictive values were characterized. Finally, analytical specificity was characterized in samples with evidence of Epstein Barr virus (EBV) (n=9), cytomegalovirus (CMV) (n=7) and endemic common cold coronavirus infections (n=12) taken prior to the current SARS CoV 2 pandemic. The diagnostic accuracy was comparable in all three assays (AUC 0.98). Using the manufacturers cutoffs, the sensitivities were 90%, 95% confidence interval,[84,94] (LIA), 93% [88,96] (CMIA), and 96% [91,98] (ECLIA). The specificities were 99.5% [98.9,99.8]( CMIA) 99.7% [99.3,99,9] (LIA) and 99.9% [99.5,99.98] (ECLIA). The LR at half of the manufacturers cutoffs were 60 (CMIA), 82 (LIA), and 575 (ECLIA) for positive and 0.043 (CMIA) and 0.035 (LIA, ECLIA) for negative results. ECLIA had higher PPV at low pretest probabilities than CMIA and LIA. No interference with EBV or CMV infection was observed, whereas endemic coronavirus in some cases provided signals in LIA and/or CMIA. Although the diagnostic accuracy of the three investigated assays is comparable, their performance in low prevalence settings is different. Introducing gray zones at half of the manufacturers cutoffs is suggested, especially for orthogonal testing approaches that use a second assay for confirmation.

COVID-19 is a recently emerging pandemic disease caused by infection with SARS-CoV-2 virus. Although 78 there are considerable differences regarding its incidence, hospitalization rate, morbidity rate, and case 79 fatality rate between different countries, disease control at the moment is uniformly achieved by strict 80 prevention measures such as social distancing, wearing of face masks, hand-washing, contact tracing 81 and testing, quarantine or isolation 1 . Whereas the diagnosis of acute disease in the medical laboratory 82 most importantly relies on RT-PCR testing, serological testing for antibodies specifically directed against 83 viral proteins of SARS-CoV2 has increasingly come into the focus of public health authorities and medical 84 institutions 2-8 . The clinical presentation of COVID-19 has been shown to be heterogeneous in severity as 85 well as in clinical signs and symptoms 9 . A substantial proportion of patients have only minimal 86 symptomatology or are even asymptomatic 10 . Currently, there is no vaccination available, and causal 87 therapies are very limited 11 . After several countries showed success in confining the progression of the 88 COVID-19 pandemic with drastic measures, there is a need to gradually cancel these measures to 89 reinstitute possibly "normal" social and economic circumstances 12,13 . To guide these actions to reverse 90 socioeconomic lockdown, knowledge on the prevalence of COVID-19 is needed 14 . Since a large 91 proportion of patients with suspected COVID-19 infection could not be tested by RT-PCR in the acute 92 phase, serological testing may gain increasing importance for retrospective clarification of clinical 93 symptoms 15 . 94 Serologic testing allows us to estimate the proportion of individuals already infected with 19, either in the total population, in healthcare workplace settings or in general workplace settings 16, 17 . It 96 facilitates contact tracing as well as surveillance and assists in the identification of individuals susceptible 97

to 18, 19 . Furthermore, individuals having had contact with confirmed COVID-19 98 patients might be interested in determining whether they developed SARS-CoV-2 specific antibodies, if 99 they did not yet have access to testing. Moreover, serological testing allows us to clarify clinical cases in 100 which RT-PCR testing has been negative despite a high pretest probability for the presence of COVID-19 101 virus [22] [23] [24] [25] . Finally, the role of specific antibodies in terms of protection against reinfection and persistence 104 over time is currently not adequately defined. 105

In the beginning of the pandemic, lateral flow tests were primarily employed to perform serological 106 SARS-CoV2 testing 26 . However, some of these tests have been criticized for poor sensitivity and 107 specificity 27 . Poor specificity has been suspected to occur due to cross-reactivity with the antibody 108 response to endemic coronaviruses causing the common cold (i.e., 28 . Some of these cross-reacting antibodies, however, have actually shown neutralizing activity 110 against SARS-CoV-2 29 . Since the antibody response in SARS-CoV-2 infection needs 2 to 4 weeks to 111 develop, false negative antibody tests can occur due to insufficient duration between the onset of clinical 112 symptoms and the time of blood sampling or insensitive measurement techniques that require large 113 quantities of antibodies for a positive result 6,12 . At the moment, it is not known how long the antibody titers 114 persist. A recent Cochrane review stated that there are currently not enough studies available for antibody 115 tests done after 35 days of symptom onset 30 . 116

Whereas ELISA tests were available relatively early during the pandemic, the supply of these 117 tests has been relatively scarce 31,32 . Only recently have assays using chemiluminescence (CLIA) become 118 available, with only a few validation data published so far 33,34 . These assays are available in large 119 quantities and can be analyzed in high-throughput settings. The different assays are directed against 120 different specific antigens, i.e., the internal nucleocapsid (N) antigen or the surface spike protein (S1 or 121 S1/S2) 27 . Not all SARS-CoV2 antibodies exhibit neutralizing properties. However, it has been shown that 122 antibodies against nucleocapsid antigen and the receptor-binding domain (RBD) of the spike protein have 123 a high correlation to virus neutralization titer 7 . 124

The predictive values of negative and positive results depend on the pretest probability of the 125 presence of COVID-19 disease. In low-prevalence settings (<5% seropositivity), positive predictive values 126 are critically dependent on specificity 35 . Since the specificity of SARS-CoV2 antibody tests has been the 127 subject of debate, false positive results can occur in low-prevalence settings 36 . False positive assay 128 results are particularly problematic in low prevalence settings, as these could lead concerned individuals 129 into a false sense of security and increase their risk of contracting COVID-19 disease through unsafe 130 behavior 13 . 131

We aimed to investigate the diagnostic specificity and sensitivity of newly released 132 chemiluminescence immunoassays (CLIAs). We investigated these assay formats in a cohort of confirmed 133 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi. org/10.1101 org/10. /2020 COVID-19 patients to assess diagnostic sensitivity. Subsequently, we assessed the diagnostic specificity 134 of these tests in a cohort of healthcare workers and a cohort of healthy blood donors. Finally, we assessed 135 the analytical specificity of the different assays in samples collected prior to the COVID-19 pandemic, 136 which may potentially contain cross-reacting antibodies. In a model, we finally related the identified 137 diagnostic characteristics to negative and positive predictive values depending on the pretest probability 138 of having had COVID-19 in the personal history. 139

Methods 141

This is a study on diagnostic tests used for detection of SARS-CoV-2 antibodies in individuals originating 143 from Switzerland and Liechtenstein. Anonymized samples originating from four different types of patients 144 were investigated with three CLIAs. The first group of patients was retrospectively assembled from 145

Liechtenstein and Swiss patients having their laboratory evaluations sent to labormedizinisches zentrum 146 Dr. Risch in Vaduz (Liechtenstein) and Buchs (Switzerland) and consisted of COVID-19 patients (mainly 147 outpatients) whose serum was drawn after COVID-19 disease was confirmed by RT-PCR between March 148 2 nd and April 23 rd , 2020 (n=145). This group was used for determination of sensitivity. The method of RT-149 PCR measurement has been conducted as reported elsewhere 37 . The patients from Liechtenstein were 150 prospectively and consecutively enrolled within a national COVID-19 cohort, whereas the Swiss patients 151 consisted from a retrospectively assembled convenience sample, both detailed in references 37,38 , The 152 second group of individuals was prospectively assembled and consisted of consecutive healthy blood 153 donors from the Blutspendedienst Graubünden without clinical suspicion of COVID-19 providing blood for 154 testing SARS-CoV2 antibodies from April 15 th to May 4 th , 2020 (n=191). In addition to fulfilling the normal 155 criteria of blood donation, these blood donors specifically responded they had had no had flu-like 156 symptoms or contact with a known COVID-19 patient during the past 14 days. The third cohort was 157 prospectively assembled within a study setting from the Kantonsspital St. Gallen and consisted of 158 healthcare workers providing a blood sample for detecting SARS-CoV2 antibodies between March 19 th 159 and April 3 rd , 2020 (n=1002) as described elsewhere 39 . Hospital admissions in this region peaked in the 160 second week of April 2020. The blood donors and the healthcare workers were used to determine 161 specificity. Since these 2 groups did not have RT-PCR testing available, samples with at least two of the 162 three chemiluminescence assays positive were excluded from this analysis, assuming that these 163 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.05.20225003 doi: medRxiv preprint individuals had occult SARS-CoV-2 infection. Such an orthogonal testing approach for SARS-CoV-2 164 antibodies has been reported to have a very high positive predictive value for COVID-19 and therefore is 165 suited to reliably exclude individuals with recent COVID-19 infection [40] [41] [42] Diagnostics assay (Elecsys ® Anti-SARS-CoV-2; ECLIA) employs a recombinantly engineered 193 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.05.20225003 doi: medRxiv preprint nucleocapsid antigen for detection of total immunoglobulin. The molecular target from the Abbott 194

Diagnostics assay (SARS-CoV-2 IgG; CMIA) is also the nucleocapsid antigen, and it measures specific 195 IgG levels. The Diasorin assay (LIAISON ® SARS-CoV-2 S1/S2 IgG; LIA) measures specific IgG directed 196 against S1/S2 antigens. To further elucidate the effects of any cross-reacting antibodies in the 3 197 chemiluminescence assays in the samples with EBV, CMV, or following endemic coronavirus, we also 198 employed the Euroimmun SARS-CoV-2 ELISA (Euroimmun, Luzern, Switzerland) to measure specific IgG 199 and IgA on a DSX instrument (Dynex Technologies, Denkendorf, Germany). The coefficients of variation 200 (CV's) of the employed methods in our hands were 2.7% for ECLIA, 3.6% for CMIA, 5.4% for LIA, 4.6% 201

for IgG ELISA, and 3.6% for IgA ELISA. 202 203

Specificity was determined in the samples originating from blood donors and healthcare workers. The 205 sensitivity of the different assays was assessed in the group of patients with RT-PCR confirmed COVID-206 19 disease. The following cut-offs provided by the manufacturers were employed: a COI (COI= cutoff 207 index) >0.9 for ECLIA, a S/C value (S/C=extinction of the patient sample divided by the extinction of the 208 calibrator) >12 for LIA, a S/C value >1.4 for CMIA, and a S/C value of >1.1 in the ELISA. We also applied 209 alternative cut-offs (half and double of the manufacturers' cut-offs), in order to better understand the 210 relationship between signal strength and associated diagnostic characteristics. Positive and negative 211 likelihood ratios (LR) were calculated for the different cut-off levels 44 . Regarding interpretation of LR, it is 212 generally acknowledged that a +LR >10 as well as a -LR <0.1 generate large and often conclusive 213 changes from the pretest to the posttest probability. A +LR between 5 and 10 as well as a -LR between 214 0.1 and 0.2 generate moderate shifts from the pretest to the posttest probability, whereas a +LR between 215 2 to 5 and a -LR from 0.2 to 0.5 generate small but sometimes important changes from the pretest to the 216 posttest probability 44 . Receiver operating characteristic (ROC) curves with the area under the curves 217 (AUCs) calculated as an indicator of diagnostic accuracy. The AUCs for the different parameters were 218 compared by the method of Hanley and McNeil. Positive and negative predictive values for each of the 219 employed assays were then plotted as a function of pretest probability, as described earlier 45 . Continuous 220 variables are given as medians and interquartile ranges [IQRs] , whereas proportions are given as 221 percentages together with 95% confidence intervals (CIs). Agreement between the two methods was 222 assessed by Cohen's kappa. The associations between variables were calculated with Spearman rank 223 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. We then calculated multilevel likelihood ratios at the manufacturers' cut-off levels as well as at half and 262 double the manufacturers' cut-off levels, i.e., a S/C of 0.7, 1.4 and 2.8 for the CMIA, respectively, a S/C 263 of 6, 12, and 24 for the LIA, and a COI of 0.5, 1, and 2 for the ECLIA. Table 1 can be seen that ECLIA, especially in low pretest probability settings, due to the high specificity has 272 somewhat higher PPVs than the other assays: at the manufacturer's cut-off, the PPV was 97% at a pretest 273 probability of 3 percent, whereas at half of the manufacturer's cut-off, the PPV at a pretest probability of 274 3% was 95%. For the LIA, the PPV at a pretest probability of 5% was 95%, whereas the same PPV at half 275 of the manufacturer's cut-off was achieved with a pretest probability of 18%. At double the manufacturer's 276 cut-off, a PPV of 95% in the LIA was achieved with a pretest probability of 2%. Finally, with the CMIA, at 277 the manufacturer's cut-off, a PPV of 95% was achieved at a pretest probability of 5%, whereas at half of 278 the manufacturer's cut-off, the same PPV was seen at a pretest probability of 23%. At double the 279 manufacturer's cut-off, the CMIA had a PPV of 95% at a pretest probability of 4%. 280

Regarding negative predictive values (NPVs), the ECLIA due to the highest sensitivity had a NPV 281 of 99% up to a pretest probability of 26% at the manufacturer's cut-off. At half of the manufacturer's cut-282 off, a NPV of 99% was seen up to a pretest probability of 30%. With the LIA, the NPV at the manufacturers' 283 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.05.20225003 doi: medRxiv preprint cut-off was at 99% up to a pretest probability of 11%, whereas at half of the manufacturer's cut-off, the 284 NPV was at 99% up to a pretest probability of 30%. In the CMIA, the NPV at the manufacturer's cut-off 285 was 99% up to a pretest probability of 21%, whereas at half of the cut-off, the NPV was 99% up to a 286 pretest probability of 26%. The present study investigated the analytical (analytical specificity), diagnostic (diagnostic sensitivity and 305 specificity), and operational characteristics (likelihood ratios, predictive values) of three highly automated 306 assays for the detection of antibodies against SARS-CoV-2. These characteristics were investigated after 307 a median of 47 days after PCR-positivity. Although the three test formats showed comparable diagnostic 308 accuracy, test performance varied regarding positive predictive values in the low-prevalence setting. 309

Finally, the investigated tests did not show interference with two commonly encountered infections, i.e., 310 EBV and CMV. There was, however, cross-reactivity in some patients with proven previous infection by 311 endemic coronaviruses for two of the three analyzed tests. 312 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi. org/10.1101 org/10. /2020 The timing of antibody development in COVID-19 disease is crucial. Long Liechtenstein setting, several situations can be described, in which the risk for patients to contract COVID-329 19 can be quantified 37 : 32% for household contacts, 13% of close working contacts, and 12-25% of 330 patients with fever >38°C and respiratory symptoms. Knowing the temporal and regional seroprevalence 331 of the region also allows for an approximation of pretest probability even without knowing the clinical 332 symptoms of a specific patient 50 . 333

The predictive values depend not only on the pretest probability but also on the sensitivity and 334 specificity of a test at a given cut-off. Negative results using the manufacturers' cut-offs had an NPV of 335 99% up to a pretest probability of 11% to 26%. At half of the manufacturer's cut-off, past COVID-19 could 336 be ruled out with a probability of 99% up to a pretest probability of 26% (CMIA) to 30% (LIA, ECLIA). 337

These pretest probabilities are in the range of those observed in symptomatic individuals. Thus, serology 338 done in patients with clinical symptoms three or more weeks before drawing blood together with 339 manufacturers' and modified manufacturers' cut-offs can be considered safe to exclude COVID-19 340 disease. Nevertheless, serological non-responders can occur with a frequency of approximately 3% and 341 may go overlooked. False negative results, if they occur at a low frequency, can be considered of minor 342 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.05.20225003 doi: medRxiv preprint importance because they are not expected to change an individual's behavior in response to its potential 343 damage. 344

Regarding PPV, which is the probability that a positive result indicates a past infection with SARS-345

CoV-2, the ECLIA with the manufacturer cut-off provided the best operational characteristics at low pretest 346 probabilities < 5%. In this assay, the PPV at 3% pretest probability was 97%, which raises the question 347 whether positive ECLIA results should be confirmed by an orthogonal testing approach 40,51,52 . When 348 taking the lower limit of the 95% CI of the specificity, i.e. 99.5%, the PPV at 1% pretest probability is 66%, 349 and 91% at 5% pretest probability. We therefore recommend continuing with the confirmation of positive 350 ECLIA results with a second assay 40 . Our data also show that at the manufacturer cut-offs, the CMIA and 351 LIA need confirmatory testing in low pretest probability (<5%) settings. Otherwise, the risk of false positive 352 results is larger than 5%. The problem of false positive results is that they can change the behavior of 353 individuals in that they will not adhere to hygienic and distancing measures after the (false) positive result 354 has been disclosed. This puts individuals at increased risk for contracting COVID-19, with its potentially 355 devastating consequences 13 . The medical laboratory thus has a great responsibility to deliver meaningful 356 results to the patients and their physicians. 357

Common recommendations on likelihood ratios state that +LR>10 and -LR<0.1 generate 358 meaningful changes from pretest to posttest probability 44 . Our findings suggest that all three assays 359 provide meaningful information, even at half of the manufacturers' cut-off values. The figures of pretest 360 probabilities against NPV illustrate that taking half of the manufacturer cut-off as a decision limit will still 361 safely rule out COVID-19: a cut-off as low as half of the manufacturer cut-off will correctly detect 98. Looking at the relationship between pretest probability and PPV at a cut-off half of the 366 manufacturer's cut-off illustrates that such a cut-off does not reliably diagnose past COVID-19 in low test 367 probability settings. However, using an orthogonal testing approach recommended by the U.S. Food and 368

Drug Administration 41 , i.e., an ECLIA result of 0.6 together with an LIA result of 6.1, would lead to a PPV 369 of 99.1% at a pretest probability of 1%. A similar result would be achieved with a CMIA result of 0.7 370 together with an LIA result of 6.1, which at a pretest probability of 2% results in a PPV of 99%. This 371 example illustrates that the introduction of gray zones should be considered not only for ELISA but also 372 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 for chemiluminescence immunoassays when offering SARS-CoV-2 testing to clinicians and public health 373 professionals 53 . 374

The fact that we found some cross-reactivity in patients with prior endemic coronaviruses raises 375 the question whether this finding represents analytical cross-reactivity or reflects cross-reactive immunity 376 conferred by recent endemic coronavirus disease. We did not conduct neutralization assays to clarify this 377 issue. However, Ng and colleagues reported that patient sera from human coronaviruses variably reacted 378 with SARS-CoV-2 S-antigen and nucleocapsid antigen, but not with the S1 subunit 29 . These patient sera 379 exhibited neutralizing activity against SARS-CoV-2 S pseudotypes according to the levels of SARS-CoV-380 2 S-binding IgG and with efficiencies comparable to those of COVID-19 patient sera 29 . In our study, we 381 had one case with a LIA signal (targeting S1-S2 antigen) and a CMIA signal (targeting nucleocapsid 382 antigen) without a signal in the IgG ELISA (which is targeted against S1). This patient had his serum 383 taken in September 2019 after infection with RCOC43 was diagnosed in January 2019. We are convinced 384 that identifying patients with endemic coronaviruses with potential neutralizing cross-reactivity will be of 385 increasing importance in the future. Whereas CMIA and LIA could play a role in identifying such 386 individuals, ECLIA is not expected to help further in this aspect, as none of the patients with endemic 387 coronavirus had a measurable antibody response. The measurements in the healthcare workers as well 388 as in the blood donors suggest that such constellations do not occur often: 1147 /1193 .1])) have unmeasurable antibody titers in the LIA, whereas this frequency amounts to 921/1193 390 (i.e., 77.2% (95% CI [74.7,79.5] )) in the CMIA. 391

Our study has strengths and limitations. A strength is that specificity has been assessed in a large 392 group of 1193 individuals without evidence of COVID-19. Such an approach offers the possibility to 393 describe the specificity with relatively narrow confidence intervals. A further strength is that we investigate 394 several potential cut-offs for clinical decision making. A limitation of the study is that samples employed 395 for evaluation of specificity were selected from contemporary and not pre-pandemic participants. Two 396 positive serology results in an orthogonal testing approach cannot provide 100% certainty that any 397 remaining false positives are truly false positive. Nevertheless, we demonstrate that combination of two 398 positive results with chemiluminescence assays has a very high positive predictive value even at low 399 pretest probabilities, comparable to that known from molecular methods 42 . Further, inclusion of the index 400 serology tests as part of the reference standard definition of absence of disease carries a risk of bias in 401 results. At low pretest probabilities, such a bias might have a considerable impact on positive predictive 402 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10. 1101 values. There are several factors mitigating such a misinterpretation: a.) utilizing an orthogonal testing 403 approach in initially positive results, b.) the fact that even in the first wave of COVID-19, prevalence in some regions of Europe was already more than 10%, which cannot be considered low 50 . 405

The specificities identified in our study from contemporary samples are comparable to those obtained in 406 a similar study on pre-pandemic samples 54 . The study is finally limited by the fact that we did not have a 407 full clinical description of the COVID-19 patients included in this study, and patients hospitalized due to 408 COVID-19 represented a minority of the COVID-19 patients. However, since the majority of patients 409 subjected to serology will originate from the outpatient setting, we believe that this fact actually strengthens 410 our findings. In sum, we think that the limitations do not invalidate our findings. 411

In conclusion, we evaluated the serology in patients at a median of 47 days following the first 412 presentation of suspected COVID-19 infection and selected individuals without COVID-19 during the 413 pandemic. We found that the diagnostic accuracy of the three investigated assays was comparable. Assay 414 cut-offs have not been designed for orthogonal testing. Introducing gray zones at half of the 415 manufacturers' cut-offs is suggested. These differentiated cut-offs would allow for safer ruling out or ruling 416 in of past COVID-19 infections. Such an approach would allow us to more appropriately select samples 417 for further testing in an independent assay in an orthogonal testing algorithm. We propose that our findings 418 be replicated in other populations. 419 420 Acknowledgments 421

The help of Toni Schönenberger and Walter Frehner in identifying samples is acknowledged. 422 423

The data used to support the findings in this study will be available from the corresponding author upon 425 request. 426 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.05.20225003 doi: medRxiv preprint

Tables 576 Table 1 . Multilevel likelihood ratios as well as sensitivity and specificity are given for the different tests at 577 different cut-off levels (manufacturers' cut-offs, half and double the manufacturers' cut-offs) for ruling in 578 or ruling out a COVID-19 diagnosis. +LR= positive likelihood ratio; -LR= negative likelihood ratio. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10. 1101 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.05.20225003 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.05.20225003 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10.1101/2020.11.05.20225003 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 6, 2020. ; https://doi.org/10. 1101 

The COVID-19 Pandemic: 458 A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control

Report from the American Society for Microbiology COVID-461 19 International Summit

Should RT-PCR be considered a gold standard in the 464 diagnosis of COVID-19

Role of serology in the COVID-19 pandemic

Early detection of SARS-CoV-2 antibodies in COVID-19 patients as 467 a serologic marker of infection

Antibody responses to SARS-CoV-2 in patients with COVID-469 19

Temporal profiles of viral load in posterior oropharyngeal 471 saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort 472 study

The Role of Antibody 474 Testing for SARS-CoV-2: Is There One?

Clinical Characteristics of Coronavirus Disease 2019 in China

Asymptomatic cases with SARS-CoV-2 infection

Antiviral therapy in management of COVID-19: a 480 systematic review on current evidence

A phased approach to 482 unlocking during the COVID-19 pandemic-Lessons from trend analysis

Waiting for Certainty on Covid-19 Antibody 484 Tests -At What Cost?

Audio Interview: The Challenges of Safe Reopening. N Engl 486

Covid-19: Lack of capacity led to halting of community testing in March, admits 488 deputy chief medical officer

Knowledge and 492 Perceptions of COVID-19 Among Health Care Workers: Cross-Sectional Study

Investigation of three clusters of COVID-19 in Singapore: 495 implications for surveillance and response measures

Connecting clusters of COVID-19: an epidemiological 497 and serological investigation

Serological immunochromatographic approach in diagnosis with 499 SARS-CoV-2 infected COVID-19 patients

Profiling Early Humoral Response to Diagnose Novel Coronavirus 501 Disease (COVID-19)

Diagnostic Performance of CT and Reverse Transcriptase-503

Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis

Nasopharyngeal COVID-19 Testing

Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or 507 CT?

Potential preanalytical and analytical vulnerabilities in the 509 laboratory diagnosis of coronavirus disease 2019 (COVID-19)

Covid-19: testing times

Will antibody tests for the coronavirus really change everything?

Serological assays for emerging coronaviruses: challenges and 514 pitfalls

Pre-existing and <em>de novo</em> humoral immunity 516 to SARS-CoV-2 in humans

Antibody tests for identification of current and past 518 infection with SARS-CoV-2

Severe Acute Respiratory Syndrome Coronavirus 2-Specific 520

Antibody Responses in Coronavirus Disease Patients

Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends

Analytical performances of a 524 chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics

Performance Characteristics of the Abbott Architect 527 SARS-CoV-2 IgG Assay and Seroprevalence in

Antibody Detection and Dynamic Characteristics in Patients with 529 COVID-19

Antibody tests for COVID-19: drawing attention to the 531 importance of analytical specificity

Flattening the curve in 52 days: characterization of the 533 COVID-19 pandemic in the Principality of Liechtenstein Swiss Med Wkly 2020:In press

Frequency of serological non-responders and false-negative 535 RT-PCR results in SARS-CoV-2 testing: a population-based study

Prevalence of SARS-CoV-2 Antibodies among Swiss 537

Centers for Disease Prevention and Control. Interim Guidelines for COVID-19 Antibody Testing

EUA authorized serology test performance

Temporal course of SARS-CoV-2 antibody positivity in 545 patients with COVID-19 following the first clinical presentation

STARD 2015: an updated list of essential items for 547 reporting diagnostic accuracy studies

Users' guides to the medical literature. III. How to use an 549 article about a diagnostic test. B. What are the results and will they help me in caring for my patients? 550 The Evidence-Based Medicine Working Group

The predictive characteristics of D-dimer 552 testing in outpatients with suspected venous thromboembolism: a Bayesian approach

Clinical Performance of Two SARS-CoV-2 Serologic 555 Assays

Diagnostic tests: a statistical review

A novel risk score to predict diagnosis with 560 coronavirus disease 2019 (COVID-19) in suspected patients: A retrospective, multicenter, and 561 observational study

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in 563

SEROCoV-POP): a population-based study

COVID-19 Diagnostics, Tools, and Prevention

Molecular and Serological Tests for COVID-19 a Comparative Review of 567 SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics

Validation of a commercially available SARS-CoV-2 569 serological immunoassay

Side by side comparison of three fully 571 automated SARS-CoV-2 antibody assays with a focus on specificity